COMMENTConcert Pharmaceuticals discontinues schizophrenia drug after trial failureExploring the pharma deals outlook in 2021Market insightMedical cannabis in EuropeArriello director of drug safety, Peter Kohut examines the potential of medical cannabis in EuropecommentLodo Therapeutics’ AI-driven natural drug discoveryinsightMarket access of orphan designated therapies at risk Concert Pharmaceuticals discontinues schizophrenia drug after trial failureExploring the pharma deals outlook in 202102/23/2024 23:26:16
Concert Pharmaceuticals discontinues schizophrenia drug after trial failure
Exploring the pharma deals outlook in 2021